🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Global Health Limited MEDANTA NIFTY_MIDNSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.medanta.org
Company Profile ↓
₹1,330.20
+2.22% 1Y
Mkt Cap₹35,742.33 Cr
P/E74.23
P/B9.01
Div. Yield0.04%
52W High₹1,427.20
52W Low₹961.10
Book Value₹147.44
EPS (TTM)₹17.92

Company Overview

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.0%.

Consistent Profit Growth

Net profit has compounded at 19.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 18.0% CAGR over the past five years.

Healthy Margins

Operating margin of 15.8% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.30.

Recent Developments

  • Mar 2026 Revenue of ₹4,410.27 Cr (+19.4% YoY); net profit ₹556.46 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.4%, earnings +15.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.0%, profit CAGR 19.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.02%
1 Year:19.44%

Compounded Profit Growth

5 Years:19.50%
1 Year:15.58%

Stock Price Performance

1 Year:+2.22%
6 Months:+13.17%
3 Months:+21.79%
1 Month:+7.61%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 79% of range
₹961.10 ₹1,427.20
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.89 · Neutral
Price Performance
1M+7.61%
3M+21.79%
6M+13.17%
1Y+2.22%
Valuation vs Sector

P/E of 74.23 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.0% over 5 years.
  • Profit CAGR of 19.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 74.2.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
74.23
Industry PE
39.97
Forward P/E
41.25
PEG Ratio
-
Book Value
₹147.44
Price to Book
9.01
P/S
8.09
EV/EBITDA
38.91
Dividend Yield
0.04%

Growth (CAGR)

Revenue 5Y
18.02%
Profit 5Y
19.50%
Revenue (YoY)
19.44%
Earnings (YoY)
15.58%

Profitability & Returns

ROCE
15.05%
ROE
14.05%
ROA
9.42%
Profit Margin
12.62%
Op Margin
15.79%
Gross Margin
77.40%
EPS (Latest Qtr)
₹5.35
EPS (TTM)
₹17.92

Balance Sheet & Liquidity

Debt/Equity
0.30
Quick Ratio
2.54
Current Ratio
2.67
Debt
₹1,190.05 Cr
Total Assets
₹5,905.00 Cr
Current Assets
₹1,674.92 Cr
Working Capital
₹1,047.79 Cr

Ownership

Promoter Holding
67.12%
Chg in Prom Hold
0.10%
FII / Inst Holding
23.10%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹35,742.33 Cr
Total Revenue (TTM)
₹4,410.27 Cr
EBITDA
₹1,016.67 Cr
Free Cash Flow
₹-264.20 Cr
Operating Cash Flow
₹714.39 Cr
Shares Outstanding
₹26.87 Cr
Gross Margin
77.40%
Payout Ratio
2.42%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MEDANTA Global Health Limited NIFTY_MIDNSEPHARMA 1,330.20 74.23 ₹35,742.33 Cr 0.04% 15.05% 14.05% 18.02% 19.50%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 707.00 Cr780.00 Cr844.00 Cr836.00 Cr809.00 Cr861.00 Cr--931.25 Cr1,030.84 Cr1,099.22 Cr1,121.05 Cr1,159.05 Cr
Cost of Revenue --------213.62 Cr239.06 Cr255.56 Cr255.66 Cr246.53 Cr
Gross Profit --------717.63 Cr791.78 Cr843.67 Cr865.39 Cr912.52 Cr
Operating Expenses 540.00 Cr595.00 Cr631.00 Cr620.00 Cr629.00 Cr675.00 Cr--542.19 Cr609.90 Cr662.45 Cr709.28 Cr735.27 Cr
Operating Income 129.00 Cr144.00 Cr170.00 Cr172.00 Cr134.00 Cr139.00 Cr--175.44 Cr181.88 Cr181.22 Cr156.11 Cr177.25 Cr
EBITDA 167.00 Cr184.00 Cr213.00 Cr216.00 Cr179.00 Cr186.00 Cr--197.72 Cr267.03 Cr266.65 Cr202.48 Cr280.50 Cr
Interest Expense 20.00 Cr18.00 Cr20.00 Cr18.00 Cr18.00 Cr18.00 Cr--15.03 Cr13.79 Cr17.11 Cr21.51 Cr26.71 Cr
Pretax Income 133.00 Cr141.00 Cr171.00 Cr172.00 Cr143.00 Cr144.00 Cr--133.44 Cr208.14 Cr199.81 Cr119.78 Cr187.28 Cr
Tax Provision 31.92 Cr39.48 Cr46.17 Cr48.16 Cr15.73 Cr37.44 Cr--32.06 Cr49.16 Cr41.41 Cr24.75 Cr45.63 Cr
Net Income 101.00 Cr102.00 Cr125.00 Cr124.00 Cr127.00 Cr106.00 Cr--101.40 Cr159.01 Cr158.44 Cr95.02 Cr143.99 Cr
Diluted EPS 3.773.804.664.614.743.96--3.775.915.893.545.35

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,382.00 Cr1,343.00 Cr1,456.00 Cr1,500.00 Cr1,447.00 Cr-2,682.80 Cr3,240.94 Cr3,692.34 Cr4,410.27 Cr
Cost of Revenue ------625.28 Cr759.36 Cr879.67 Cr996.80 Cr
Gross Profit ------2,057.52 Cr2,481.58 Cr2,812.68 Cr3,413.47 Cr
Operating Expenses 1,081.00 Cr1,218.00 Cr1,283.00 Cr1,309.00 Cr1,250.00 Cr-1,558.46 Cr1,823.32 Cr2,129.21 Cr2,716.91 Cr
Operating Income 231.00 Cr39.00 Cr70.00 Cr77.00 Cr74.00 Cr-499.06 Cr658.26 Cr683.47 Cr696.56 Cr
EBITDA 301.00 Cr125.00 Cr172.00 Cr192.00 Cr197.00 Cr-676.67 Cr872.37 Cr906.26 Cr1,016.67 Cr
Interest Expense 14.00 Cr28.00 Cr38.00 Cr57.00 Cr73.00 Cr-77.46 Cr72.54 Cr65.26 Cr79.11 Cr
Pretax Income 262.00 Cr60.00 Cr83.00 Cr64.00 Cr32.00 Cr-449.29 Cr627.10 Cr647.26 Cr715.02 Cr
Tax Provision 91.70 Cr27.00 Cr31.54 Cr27.52 Cr3.52 Cr-123.21 Cr149.04 Cr165.94 Cr160.95 Cr
Net Income 170.00 Cr33.00 Cr51.00 Cr36.00 Cr29.00 Cr-326.08 Cr478.19 Cr481.44 Cr556.46 Cr
Diluted EPS 35.106.7810.447.365.817.7312.5717.8017.92-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,485.00 Cr1,984.00 Cr2,430.00 Cr2,666.00 Cr2,694.00 Cr-4,115.97 Cr4,304.07 Cr4,766.23 Cr5,905.00 Cr
Current Assets ------1,579.49 Cr1,508.73 Cr1,533.12 Cr1,674.92 Cr
Cash & Equivalents ------767.24 Cr424.61 Cr230.20 Cr127.33 Cr
Inventory ------60.37 Cr66.85 Cr67.14 Cr78.98 Cr
Receivables ------194.20 Cr215.31 Cr291.86 Cr411.19 Cr
Total Liabilities ------1,687.76 Cr1,398.48 Cr1,378.72 Cr1,920.73 Cr
Current Liabilities ------572.55 Cr617.73 Cr618.82 Cr627.13 Cr
Long Term Debt ------737.12 Cr283.47 Cr264.10 Cr601.12 Cr
Total Debt 165.00 Cr456.00 Cr787.00 Cr929.00 Cr931.00 Cr-1,121.95 Cr801.87 Cr717.73 Cr1,190.05 Cr
Total Equity 1,024.00 Cr1,184.00 Cr1,295.00 Cr1,349.00 Cr1,383.00 Cr-2,428.21 Cr2,905.63 Cr3,386.41 Cr3,961.57 Cr
Shares Outstanding ------26.82 Cr26.85 Cr26.86 Cr26.87 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 228.00 Cr63.00 Cr166.00 Cr175.00 Cr242.00 Cr-644.52 Cr612.08 Cr623.76 Cr714.39 Cr
Investing Cash Flow -241.00 Cr-69.00 Cr-249.00 Cr-87.00 Cr-239.00 Cr--342.35 Cr-440.80 Cr-720.94 Cr-1,089.11 Cr
Financing Cash Flow -7.00 Cr9.00 Cr97.00 Cr-1.00 Cr-81.00 Cr-345.64 Cr-513.92 Cr-97.23 Cr271.85 Cr
Capital Expenditure -157.00 Cr-144.00 Cr-299.00 Cr-188.00 Cr-142.00 Cr--235.99 Cr-278.58 Cr-647.91 Cr-978.59 Cr
Free Cash Flow 71.00 Cr-81.00 Cr-133.00 Cr-13.00 Cr100.00 Cr-408.53 Cr333.50 Cr-24.16 Cr-264.20 Cr
Net Change in Cash -20.00 Cr3.00 Cr14.00 Cr87.00 Cr-78.00 Cr-647.81 Cr-342.63 Cr-194.41 Cr-102.87 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------76.7%76.6%76.2%77.4%
Operating Margin % 16.7%2.9%4.8%5.1%5.1%-18.6%20.3%18.5%15.8%
Net Margin % 12.3%2.5%3.5%2.4%2.0%-12.2%14.8%13.0%12.6%
ROE % 16.6%2.8%3.9%2.7%2.1%-13.4%16.5%14.2%14.0%
ROCE % ------14.1%17.9%16.5%13.2%

Shareholding Pattern

Insiders
67.12%
Institutions
23.10%
Public Float
70.26%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDANTA

Google News Sun, 18 Jan 2026

Global Health Limited (NSE:MEDANTA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPd3BJXzBNMEVFS0RFcWJWU2FzVEdjRElxcHVmSXJGVmF0WnVLUV9MdVM0YzdLX2pxMzN6Y2ZkN0dfbkVacEx1UjJ3NmhwWmNtazZONWc4dGs3Tml1b1ptdmhuQkxOakpWNXNVQV9MYUh1NGRnTGNReWtoRDRHOF9HYTA5RUtIcnJVVHY3MW…

Google News Sat, 23 May 2026

Medanta: What Should Investors Do? - BusinessLine

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOdDdtWUQtWDdMeGY0RUQ3Z2IyWFVTeTliTjhvY0tpRlhpelpvVXhqb25BZlFGd09vLUVkVHNvb1FBRmppa0dLaDZlNVFWLW9EUWVfLXIwQ24zd2NHWkI1ZW1sTEFsQ3ktdDNJVDhBNW1TUUxhaUtHeXpLNFNWdnJmZUxUYnEyWmM1alZNY1…

Google News Wed, 25 Mar 2026

Medanta valuation attractive post correction; JM Financial pegs 42% upside - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQbVk0WnJGcHp2YmdiNjVEdU1xR2pNLUNkS00tdC1hcHItVEpHalZuUTdvcEtvLXhSeHBPSWRCU3owNlk0alVXbE5aM3FXX1pkUDN6SkdDQkNEejNRelFPWkxINUZxaTJNbDV2MU55TmRZWkwyWm9XUXktYjQyQldCZWJCdWdsNGNoNXplLX…

Google News hu, 25 Jun 2026

HDFC Mutual Fund buys additional 10 lakh shares of Global Health for Rs 130 crore - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQMEQ3a0JnODdOdjB1QWVNTkNUeXlVTncyWkwza0NLY0I0V25aZ0lmWE1HOWpkM21aeldfb1NWN3FOcXhDSENONEdEenNCd25sZEVxLTU5N2k1R3AyTkkxcjJjN2F2blJ5aHNlVTFRNVFJUTMzYUJzNUl4Ym13eDJ2QWphWk5RcXlQNE1MRE…

Google News Sun, 17 May 2026

Global Health Limited (NSE:MEDANTA) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQZlUtTFM4dUhDYXZxMElOU0lmcW9LNEpqLUtZN0FQTHVZNDY4bWtPMGFvcmhvY2QweVptbjVHNVhKYUdvcmxpRGUtV0lEY1pRUnIzQ01WaG01NVN0RXc1dTI5UVl4eFV0ZThrUkZtbEF3UTJEUnc4LXFMVEo2aTBOaHduaHFXMjFQb2dfdW…

Google News Mon, 29 Jun 2026

Trade Spotlight: How should you trade Medanta, Tata Motors, Cholamandalam Investment, Radico Khaitan,... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMirgJBVV95cUxPb1RLN0dRaENEUnpOZlp5NmVuVE5NZXF6Sy1GUnhVclU4ckdLa3JDeGdIR1ROMGlZZ1pHTlJ3WFhUQ1k5WF9VRFhYZFpMYzVhRThkUVJLS1AxWkRDYkF6RFpUVHhKcUlqemNfdmwxRklyMjhjNFRiMWNQWjNWbXBFd0Z1blRrLVNBU1d3Ul…

MEDANTA — Frequently Asked Questions

What is the current share price of Global Health Limited (MEDANTA)?

As of 2026-07-15 09:52 IST, Global Health Limited (MEDANTA) trades at ₹1,330.20 on NSE. Its 52-week range is ₹961.10 to ₹1,427.20.

What is the market capitalisation of MEDANTA?

Global Health Limited (MEDANTA) has a market capitalisation of ₹35,742.33 Cr on NSE.

What is the P/E ratio of MEDANTA?

MEDANTA trades at a trailing price-to-earnings (P/E) ratio of 74.23. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 9.01.

Does MEDANTA pay a dividend?

Global Health Limited (MEDANTA) currently offers a dividend yield of 0.04%.

What is the return on equity (ROE) of MEDANTA?

MEDANTA has a return on equity (ROE) of 14.05%. Its return on capital employed (ROCE) is 15.05%.

Is MEDANTA a good stock to buy?

This page provides a data-driven analysis of Global Health Limited (MEDANTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space